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Summary
Objective: Growth factor therapy may be useful for stimulation of cartilage matrix synthesis and repair. Thus, the purpose of our study was to
further understand the effect of combined insulin-like growth factor-1 (IGF-1) and osteogenic protein-1 (OP-1) treatment on the matrix synthe-
sized by human adult normal and osteoarthritic (OA) chondrocytes.
Design: Chondrocytes were isolated post-mortem from articular cartilage from tali of normal human donors and femoral condyles of OA pa-
tients undergoing knee replacement surgery. Cells were cultured in alginate beads for 21 days in four experimental groups: (1) ‘‘mini-ITS’’
control; (2) 100 ng/ml IGF-1; (3) 100 ng/ml OP-1; (4) IGF-1þOP-1, each at 100 ng/ml. Beads were processed for histological (Safranin O
and fast green), morphometrical and immunohistochemical (aggrecan, decorin, type I, II, VI, and X collagens, and ﬁbronectin accumulation)
analyses.
Results: Histology showed that IGF-1 alone did not induce substantial matrix production. OP-1 alone caused a considerable matrix formation,
but the highest matrix accumulation by normal and OA chondrocytes was found when OP-1 and IGF-1 were added together. Morphometrical
analysis indicated larger matrices produced by OA chondrocytes than by normal cells under the combined treatment. All tested matrix proteins
were more abundant in the combination group. Type X collagen was detected only under the combined OP-1 and IGF-1 treatment and was
present at very low levels. Type I collagen was found only in OA chondrocytes.
Conclusions: The results obtained in the current study suggest that combined therapy with IGF-1 and OP-1 may have a greater potential in
treating cartilage defects seen in OA than use of either growth factor alone.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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International
Cartilage
Repair
SocietyIntroduction
Cartilage repair is a major challenge faced by clinicians and
scientists in the ﬁeld of orthopedics, where numerous efforts
are being made to ‘‘re-establish a structurally and function-
ally competent repair tissue’’1. In this light, growth factor
therapy has received considerable attention due to the abil-
ity of different anabolic mediators to induce and facilitate
cartilage matrix synthesis and repair.
In adult articular cartilage, chondrocytes occupy less than
5% of the total tissue volume, yet they are responsible for
the extracellular matrix (ECM) synthesis, assembly, regula-
tion, and maintenance. Chondrocytes maintain normal car-
tilage homeostasis through the balance between anabolic
and catabolic activities. The growth factors that are the
focus for the current study, insulin-like growth factor-1
(IGF-1) and osteogenic protein-1 (OP-1) [also known as
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ﬁed endogenously in adult articular cartilage2,3 and shown
to stimulate signiﬁcant anabolic activities of human, bovine,
monkey, goat, and sheep chondrocytes4e11. OP-1 induced
the synthesis of major ECM components, aggrecan, colla-
gen type II, and hyaluronan (HA)7,8,12 with continued
expression of the differentiated chondrocyte phenotype
(no type I or type X collagen synthesis)7,13 and no induction
of chondrocyte proliferation14. Furthermore, OP-1 stimu-
lated the synthesis of the HA receptor, CD44, and HA
synthase-2 thus promoting the formation and retention of
the ECM8,15. Importantly, it counteracted catabolic events,
such as interleukin-1b, ﬁbronectin fragment and HA hexa-
saccharide-induced cartilage degeneration12,16,17.
In cartilage, IGF-1 could function in a paracrine and auto-
crine manner to stimulate matrix synthesis18e21 and inhibit
matrix degradation by down-regulating matrix metalloprotei-
nases and inﬂammatory cytokines 22e24. IGF-1 also
promotes chondrocyte survival25. The overexpression of
human IGF-1 induced new tissue formation in an ex vivo
model of articular cartilage transplantation20. However,
there is a limited amount of data pertaining to human carti-
lage showing changes in response to IGF-1 especially in21
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strated a lack of response to IGF-1 by OA chondrocytes
in comparison to normal ones, where the cells studied
were from cartilage obtained at the time of joint replacement
surgery, which likely represents end-stage OA. It is not
known if a reduced response to IGF-1 contributes to earlier
phases of the disease. Studies by Loeser et al.11,25 support
the notion of a reduced IGF-1 response in chondrocytes
from cartilage with OA changes. However, the effect of
OA score in those studies was more variable than the effect
of age and after adjustment for age, only proline incorpora-
tion and not sulfate incorporation was signiﬁcantly reduced
in OA cells11. It appears that the response to IGF-1 may be
inﬂuenced by age and by disease severity and that the
mechanisms responsible for the reduced responsiveness
may differ between early and late-stage OA chondrocytes.
Although IGF-1 has been shown to be the major stimula-
tor of proteoglycan (PG) synthesis present in synovial ﬂuid
and fetal calf serum, Schneiderman et al.2 have suggested
that the amount of IGF-1 present in normal adult articular
cartilage (about 10 ng/g tissue) is not sufﬁcient to make it
a major stimulator of PG synthesis in situ, which implies
a possible role of other anabolic factors as was hypothe-
sized by Trippel27. This is supported by study of Fan
et al.28, which showed that OA chondrocytes express statis-
tically higher levels of anabolic genes, aggrecan and colla-
gen type II, than normal chondrocytes in response to
stimulation by OP-1.
Only limited studies have addressed questions of carti-
lage metabolism and combined growth factor therapy. It
has been shown that either epidermal growth factor
(EGF)29, ﬁbroblast growth factor (FGF)6,29,30, or transform-
ing growth factor-b (TGF-b)6,31e33 can modulate the
response of chondrocytes to IGF-1. Previously, we showed
that addition of OP-1 to IGF-1 induces an additive effect of
both factors on PG synthesis and a synergistic effect on cell
proliferation25. Similar effects on cell differentiation and pro-
liferation by these two growth factors have been also dem-
onstrated in rat osteoblastic cells34. Furthermore, autocrine
IGF-1 production could be up-regulated by OP-1 at both
transcriptional and posttranscriptional level in osteoblastic
cells35,36 and in adult articular chondrocytes24. In bone
cells, OP-1 modulated expression of the components of
the IGF-1 regulatory system37.
The objective of this continuing study was to further un-
derstand the effect of combined treatment and to identify
and visualize which matrix constituents are synthesized in
response to the combination of IGF-1 and OP-1 by human
adult normal and OA chondrocytes cultured for long-term in
alginate beads.
Materials and methods
MATERIALS
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM), Ham’s
F-12, fetal bovine serum (FBS), and Gentamycin were
purchased from Invitrogen (Carlsbad, CA). Mini-insulin,
transferrin, and selenous acid medium (mini-ITS) was pro-
duced as previously described25. Low-viscosity alginate
(Keltone, LV) was obtained from Kelco (Chicago, IL).
‘‘Live/Dead Viability/Cytotoxicity Kit’’ was obtained from
Molecular Probes (Eugene, OR). Safranin O and fast green
dyes were purchased from Fisher Scientiﬁc (Pittsburgh,
PA). Anti-ﬁbronectin monoclonal antibody was purchased
from Chemicon International Inc (Temecula, CA); anti-
aggrecan, anti-decorin, anti-type II collagen and anti-typeVI collagen monoclonal antibodies were purchased from
the Developmental Studies Hybridoma Bank, University of
Iowa (Iowa City, IA). Anti-type I collagen polyclonal anti-
body38 and monoclonal antibody to type X collagen39
were provided by Dr Aigner. Recombinant human OP-1
(rhOP-1) was kindly provided by Stryker Biotech (Hopkin-
ton, MA). Recombinant human IGF-1 was a gift from Chiron
Corp. (Emeryville, CA). Peroxidase labeled goat anti-mouse
IgG was purchased from Organon Technika Corp.
(Durham, NC). All other used chemicals were molecular
biology grade and purchased either from Sigma (St. Louis,
MO) or Fischer Scientiﬁc (Pittsburgh, PA). Pronase and
Collagenase P (Clostridium histolyticum) were purchased
from Calbiochem (San Diego, CA) and Boehringer Man-
nheim (Indianapolis, IN), respectively.
CHONDROCYTE ISOLATION AND CULTURE
Normal cartilage was obtained from the ankle joints of
seven tissue donors within 24 h of death through collabora-
tion with the Gift of Hope Organ and Tissue Donor Network
(Elmhurst, IL) with Institutional Review Board Approval and
appropriate consent. The donors had no documented his-
tory of joint disease. Each joint was graded with a modiﬁed
Collins scale for morphological appearance as described40.
For this study only normal joints of grade 0e1 were used.
The meanSD age of the donors was 45 8 years (range
20e76). OA cartilage was obtained from patients undergo-
ing total knee joint arthroplasty (n¼ 6) at the Department of
Orthopedic Surgery at Rush University Medical Center
within 3 h of surgery, with Institutional Review Board
Approval and appropriate consent. The average age of
OA patients was 66 11 years (range 51e78).
Cartilage was dissected from the joints, with care taken to
avoid underlying bone and osteophytes. The tissue was di-
gested in DMEM/Ham’s F-12 medium (1:1) containing 0.2%
pronase in an incubator with continuous agitation for 1 h,
and then overnight with 0.025% collagenase P in DMEM/
Ham’s F-12 supplemented with 5% FBS. After isolation,
the cells were counted. The initial viability prior to culture
was assessed using trypan blue dye exclusion assay and
was determined to be >90%. The cells were resuspended
at 2 106/ml in sodium alginate. Alginate beads were pro-
duced as previously described11, resulting inw20,000 cells
per bead.
Alginate beads were cultured at eight beads per well in
24-well plates, in serum-free DMEM/Ham’s F-12 (1:1;
1 ml/well). All media were supplemented with 1% mini-
ITSþ, which contains 5 nM insulin (‘‘mini’’-dose insulin so
that the IGF-1 receptor is not stimulated), 2 mg/ml transfer-
rin, 2 ng/ml selenous acid, 25 mg/ml ascorbic acid, and
bovine serum albumin/linoleic acid at 420/2.1 mg/ml11.
Cultures were maintained for 21 days. The beads were
divided into four experimental groups: media control; beads
treated with IGF-1 (100 ng/ml); beads treated with OP-1
(100 ng/ml); and beads treated with the combination of
IGF-1 (100 ng/ml) and OP-1 (100 ng/ml). Medium was
changed every 48 h, with the addition of fresh growth
factors to the treated wells.
HISTOLOGY AND IMMUNOHISTOCHEMISTRY
ON ALGINATE BEADS
To visualize the matrix deposited by chondrocytes, algi-
nate beads were ﬁxed in 4% paraformaldehyde in 0.1 M
cacodylate buffer (pH 7.4) containing 10 mM CaCl2 for 4 h
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(pH 7.4) containing 50 mM BaCl2, dehydrated through serial
alcohols and xylene, embedded in parafﬁn, sectioned at
6 mm and processed for histology and immunohistochemis-
try as described41. For histology, the beads were stained
with Safranin O and fast green42.
For immunohistochemistry, before incubation with the
primary antibodies, bead sections were digested with kera-
tanase [Pseudomonas sp; EC 3.2.1.103 (0.01 U/ml)],
keratanase II [Bacillus sp. KS 36 (0.0001 U/ml)], and chon-
droitinase ABC [Proteus vulgaris; EC 4.2.2.2 (0.01 U/ml)] in
100 mM Tris/50 mM Na-acetate buffer (pH 6.5) at 37C for
90 min to increase the penetration of antibodies into the
matrix. All three proteinases were obtained from Seikagaku
(Tokyo, Japan). For negative controls, the primary anti-
bodies were replaced with either normal serum or second-
ary antibody alone. Anti-type I and anti-type X collagen
antibodies were applied at 1:500 and 1:1000 dilutions; all
other primary antibodies were applied at a 1:100 dilution.
To detect aggrecan, decorin, and collagen type II, Immuno-
Pure ABC Alkaline Phosphatase mouse IgG staining kit for
immunohistochemistry was used (Pierce Biotechnology,
Rockford, IL). To localize ﬁbronectin and type VI collagen,
horseradish-peroxidase conjugated mouse IgG secondary
antibody was used; the sections were counterstained with
hematoxylin. Type I and X collagens were detected accord-
ing to the protocol described by Aigner et al.43, in which
cartilage sections were enzymatically pretreated with hyal-
uronidase (2 mg/ml in phosphate buffer saline (PBS), pH
5.0, 60 min at 37C) and protease XXIV (0.02 mg/ml in
PBS, pH 7.3, 60 min at 37C), incubated overnight with
corresponding antibodies at 4C, and visualized with
a streptavidinebiotin complex kit (Super Sensitive Immuno-
detection System for mouse primary antibodies; Biogenex,
San Ramon, CA). The red stain was fast red, a substrate
for the alkaline phosphatase used in the detection kit; coun-
terstaining was done with hematoxylin to stain the nuclei of
the cells. Evaluation and documentation of the results was
done with a Nikon Eclipse 600 microscope (Tokyo, Japan)
with a Spot 2 camera; the pictures were taken with the
MetaMorph software program (Universal Imaging Corpora-
tion, PA, USA).MORPHOMETRICAL ANALYSIS
Safranin O stained sections underwent morphometrical
analysis under 400 magniﬁcation to quantify the size of
the newly deposited matrix using a Nikon Eclipse E600
microscope connected to a PC running MetaMorph Imaging
series 6.1. Using this software, the area occupied by each
chondrocyte and its newly synthesized matrix was deter-
mined by selecting the area of the ‘‘cavity’’ left in the algi-
nate bead, forming a better representation of the actual
size of the newly synthesized matrix before shrinkage arti-
fact from histological preparation [Fig. 2(A)]. The control
and all experimental groups were subjected to the morpho-
metrical analysis. The data were collected for 17e38 cells/
cell clones with their surrounding matrix for each group in
a blind manner and normalized to the number of cells within
selected area. The size of the cell per se was not subtracted
from the size of the matrix since it was difﬁcult to distinguish
between cell-associated matrix and cell itself. The statistical
signiﬁcance of results was determined by analysis of
variance, using Prizm software and one-way ANOVA. Com-
parison of the different growth factor treatments was done
with two-tailed student’s t test.
Results
HISTOLOGY
Staining of alginate beads with Safranin O and fast green
allowed visualization of newly synthesized matrix. Nonspe-
ciﬁc binding of Safranin O dye to the negatively charged
alginate matrix produced intense red stain, while matrix syn-
thesized by chondrocytes appeared with a lighter intensity
of red (Fig. 1). In the ITS control group [Fig. 1(A and E)]
barely visible matrix was seen around chondrocytes. The
histological appearance of alginate beads cultured in the
presence of growth factors indicated the highest matrix
formation under the treatment with combined IGF-1 and
OP-1 [Fig. 1(D and H)]. In the IGF-1 alone group [Fig. 1
(B and F)] no signiﬁcant matrix deposition was noticed, es-
pecially by OA chondrocytes. OP-1 alone [Fig. 1(C and G)]
caused a considerable matrix formation by both normalFig. 1. Safranin O staining of normal (AeD) and OA (EeH) chondrocytes cultured in alginate beads. (A and E) Cells cultured in the presence of
mini-ITS; (B and F) cells cultured in the presence of IGF-1 (100 ng/ml); (C and G) cells cultured in the presence of OP-1 (100 ng/ml); (D and H)
cells cultured in the presence of combined OP-1 and IGF-1. Original magniﬁcation 400.
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Fig. 2. Morphometrical analysis of the matrix deposited by normal
and OA chondrocytes cultured in alginate. (A) Representative pic-
ture with the outline of the cell with surrounding ECM deposited
within alginate; (B) average size of the matrix produced by chondro-
cytes; comparison is made between treatment groups separately
for cells isolated from each tissue type (normal or OA). For normal
chondrocytes the differences were statistically signiﬁcant between
the following groups: OP-1 vs control or vs IGF-1, P < 0.001;
OP-1þ IGF-1 vs control or vs IGF-1, P< 0.001; OP-1þ IGF-1 vs
OP-1, P< 0.05. For OA chondrocytes, OP-1 vs control or vs IGF-1,
P < 0.001; OP-1 þ IGF-1 vs control or vs IGF-1 or vs OP-1,
P< 0.001. Comparison was also made between the tissue types
and statistically signiﬁcant differences (P < 0.02) were found
between normal and OA chondrocytes treated with OP-1þ IGF-1.and OA chondrocytes, but less than in the combination
group. Of note, no visible differences were observed in
the amount of matrix deposited within the alginate by nor-
mal and OA chondrocytes whether in the presence or ab-
sence of growth factors. The apparent shrinkage of the
matrix within the areas occupied by chondrocytes is be-
lieved to be due to the artifacts produced by ﬁxation and
processing procedures.
MORPHOMETRY
To quantify the amount of matrix deposited by chondro-
cytes in alginate, we applied morphometrical analysis,
where the size of the matrix surrounding each cell or clone
of cells in square micrometer was divided by the number of
chondrocytes residing within this area [example is shown in
Fig. 2(A)]. IGF-1 alone did not induce signiﬁcant matrix
accumulation in comparison to control [Fig. 2(B)], while
OP-1 was able to stimulate matrix synthesis by both normal
and OA chondrocytes. The size of the matrix produced by
OP-1 was signiﬁcantly different in comparison to IGF-1
treatment or ITS control (2.6-fold as compared to IGF-1
treatment and 3.3-fold in comparison to ITS control for nor-
mal chondrocytes; 2.9-fold and 2.4-fold correspondingly for
OA chondrocytes; P< 0.001). The largest matrix was syn-
thesized by chondrocytes stimulated by the combination
of growth factors [Fig. 2(B)]. The effect was statistically sig-
niﬁcant in comparison to the control (4.4-fold increase for
normal chondrocytes and 5.9-fold increase for OA chondro-
cytes; P< 0.001), IGF-1 (3.5-fold and 7-fold correspond-
ingly; P< 0.001), or OP-1 alone treatments (1.3-fold,
P< 0.05 for normal chondrocytes and 2.4-fold, P< 0.001
for OA cells). Noteworthy, although combined treatment
induced chondrocyte proliferation, as shown here and in
a previous study25, matrix production per cell was still great-
est for the combination of both growth factors. We also com-
pared the response of normal and OA chondrocytes to the
stimulation with growth factors and found no statistical dif-
ferences in the size of the matrix synthesized in the control,
IGF-1 alone, or OP-1 alone groups. Under combined treat-
ment, the size of newly synthesized matrix was statistically
larger in OA chondrocytes than in normal chondrocytes
[1.5-fold difference; P< 0.02; Fig. 2(B)].Fig. 3. Immunostaining of chondrocytes in alginate beads with anti-type II collagen antibody. (AeD) Chondrocytes isolated from normal
cartilage; (EeH) chondrocytes isolated from OA cartilage. (A and E) Cells cultured in media with mini-ITS; (B and F) cells treated with
IGF-1; (C and G) cells treated with OP-1; (D and H) cells treated with combined OP-1 and IGF-1. Original magniﬁcation 400.
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Type II Collagen Staining
Immunostaining with anti-type II collagen antibody
showed that both normal and OA chondrocytes cultured in
alginate beads were able to synthesize and deposit type II
collagen under stimulation with growth factors. In the control
groups, treatment with ITS media did not appear to increase
levels of type II collagen in the matrix [Fig. 3(A and E)]. Low
levels of type II collagen protein were observed in the pres-
ence of IGF-1 [Fig. 3(B and F)]. Type II collagen was primar-
ily localized in the interterritorial, further-removed matrix. In
the OP-1 treated beads, the pattern of type II collagen dis-
tribution and localization was similar for normal and OA
chondrocytes. In both cell types collagen type II was mainly
detected in the interterritorial matrix at the edges of the algi-
nate matrix [Fig. 3 (C and G)], although it appears that less
type II collagen was detected in OA chondrocytes than in
normal cells. The highest levels of type II collagen were
identiﬁed under combined treatment with growth factors
[Fig. 3(D and H)], where type II collagen protein was local-
ized in all matrix compartments: pericellular, territorial, andinterterritorial. The intensity of stain was similar for both
normal and OA cells.
Aggrecan Immunostaining
In contrast to collagen type II, some aggrecan synthesis
was detected in the beads from the mini-ITS control groups
of normal [Fig. 4(a, A)] and OA chondrocytes [Fig. 4(b, A)].
Stimulation with IGF-1 alone induced some additional ag-
grecan accumulation in the interterritorial matrix by normal
cells [Fig. 4(a, B)], but no such response was evident for
OA cells [Fig. 4(b, B)]. The effect of OP-1 treatment was
much more pronounced. In beads with normal cells, OP-1
stimulated aggrecan accumulation primarily in the interterri-
torial matrix with some aggrecan presence in the pericellu-
lar and territorial matrices [Fig. 4(a, C)]. In beads with OA
cells, OP-1 stimulated a very strong staining for aggrecan
which was found mainly in the pericellular and territorial ma-
trices with only weak stain in the interterritorial areas
[Fig. 4(b, C)]. Combined treatment induced more synthesis
of the aggrecan core protein in either cell type than each
growth factor separate. The distribution and localization ofFig. 4. Immunohistochemistry of chondrocytes cultured in alginate beads and treated with growth factors. (4a) Normal chondrocytes; (4b) OA
chondrocytes. (AeD) Chondrocytes stained with anti-aggrecan antibody (Aggr); (EeH) chondrocytes stained with anti-type VI collagen anti-
body (ColVI); (IeL) chondrocytes stained with anti-decorin antibody (Dec); (MeP) chondrocytes stained with anti-ﬁbronectin antibody (Fbrn).
(A, E, I, and M) mini-ITS control; (B, F, J, and N) cells treated with IGF-1; (C, G, K, and O) cells treated with OP-1; (D, H, L, and P) cells treated
with combined OP-1þ IGF-1. Aggrecan and decorin immunostaining was developed with ImmunoPure ABC Alkaline Phosphatase staining
kits that produced blue color; type VI collagen and ﬁbronectin stains were developed by the application of horseradish-peroxidase conjugated
secondary antibodies that produced brown color. Original magniﬁcation 400.
426 S. Chubinskaya et al.: Matrix formation under combined IGF-1 and OP-1Fig. 4 (continued)aggrecan was similar for both normal [Fig. 4(a, D)] and OA
chondrocytes [Fig. 4(b, D)] and it was detected in the terri-
torial and interterritorial matrices.
Type VI Collagen
Type VI collagen was detected in all experimental groups
including mini-ITS controls [Fig. 4(a and b, E)]. In normal
chondrocytes [Fig. 4(a)] no apparent differences in the
amount of type VI collagen and patterns of its distribution
were found between treatment groups [Fig. 4(a, EeH)]. In
all groups type VI collagen was primarily localized in the
pericellular matrix. In OA chondrocytes [Fig. 4(b)] in the
group of combined OP-1 and IGF-1 [Fig. 4b(H)], in addition
to the pericellular localization type VI collagen was also
largely present in the interterritorial matrix. Surprisingly,
the highest intensity of cellular type VI collagen staining in
OA chondrocytes was found under the treatment with
IGF-1 alone [Fig. 4(b, F)].
Decorin
Decorin was barely detected on the background levels in
the mini-ITS control beads containing either OA [Fig. 4(b, I)]
or normal chondrocytes [Fig. 4(a, I)]. IGF-1 treatment
induced very low accumulation of decorin by both cell types
and it was localized in all three matrix compartments[Fig. 4(a and b, J)]. The OP-1 effect was more pronounced
than that of IGF-1 on decorin synthesis and the amount of
decorin deposited by OA chondrocytes [Fig. 4(b, K)] was
more abundant than by normal cells [Fig. 4(a, K)]. Combina-
tion of the two growth factors stimulated the highest decorin
synthesis in normal [Fig. 4(a, L)] and OA chondrocytes
[Fig. 4(b, L)]. In both cell types decorin was primarily local-
ized in the interterritorial matrix; however, in normal chon-
drocytes decorin matrix appeared of more native structural
organization and resembled a honeycomb structure
[Fig. 4(a, L)]. OA chondrocytes did not reveal such distinct
pattern [Fig. 4(b, L)].
Fibronectin
Fibronectin protein was detected in all experimental
groups in both normal [Fig. 4(a, MeP)] and OA chondrocytes
[Fig. 4(b, MeP)]. Overall, immunostaining with ﬁbronectin
antibody appeared stronger for normal cells than for OA
cells. In the mini-ITS control group [Fig. 4(a and b, M)] and
in the IGF-1-treated [Fig. 4(a and b, N] chondrocytes ﬁbro-
nectin was primarily localized in the pericellular matrix;
however, in the presence of OP-1 [Fig. 4(a and b, O)] or
combined OP-1 and IGF-1 [Fig. 4(a and b, P)] some ﬁbro-
nectin was also detected in the interterritorial matrix at the
edges of the lacunas.
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X Collagen Antibodies
To verify the phenotype of chondrocytes cultured in al-
ginate beads for 21 days we stained the beads with
antibodies against type I and type X collagens. We found
low to moderate levels of type I collagen primarily present
in OA chondrocytes [Fig. 5(C and D)] and more in cells
treated with combined OP-1 and IGF-1 [Fig. 5(D)]. In
other experimental groups [for example, mini-ITS control,
Fig. 5. Immunostaining of normal (A and B; E and F) and OA (C and D; G and H) chondrocytes with anti-type I (AeD) and anti-type X (EeH)
collagen antibodies. (A, C, E, and G) Cells cultured in the presence of mini-ITS control; (B, D, F, and H) cells treated with combined
OP-1þ IGF-1. Original magniﬁcation 400.
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barely detectable or was below the detection limit
[Fig. 5(A and B)]. Staining of normal [Fig. 5(E and F)]
and OA chondrocytes [Fig. 5(G and H)] with anti-type X
collagen antibody showed no detectable type X collagen
in cells treated with ITS control [Fig. 5(E and G)] or in
all other experimental groups (not shown) except for
chondrocytes cultured under combined treatment
[Fig. 5(F and H)]. In this group in both types of cells
(normal and OA) collagen type X was present at very
low, almost negligible levels.
Discussion
This is a continuing study of Loeser et al.25 that directly
compares the ability of IGF-1, OP-1, or their combination
to stimulate matrix production by normal and OA chondro-
cytes. In this study, we found that OA chondrocytes are
metabolically active and that they could respond anaboli-
cally to the treatment with growth factors by producing car-
tilage-speciﬁc proteins. Similar ﬁndings were reported by
Fan et al.28, in which OA chondrocytes showed a higher ex-
pression of anabolic genes, collagen type II and aggrecan,
when stimulated by OP-1. Here we also found that normal
and OA chondrocytes isolated from their native matrix and
cultured under conditions deﬁned in this study respond bet-
ter to OP-1 than to IGF-1, but only with regard to the synthe-
sis of certain major cartilage matrix molecules: collagen
type II, aggrecan, and decorin. Clearly, the combination of
IGF-1 and OP-1 showed a synergistic effect on the synthe-
sis of these cartilage matrix constituents by both normal and
OA chondrocytes. Collagen type II, aggrecan and decorin
were more abundant under the combined treatment than
under the treatment with each growth factor separately.
Moreover, as shown previously25, the combined treatment
caused new effects including increased proliferation and
cell survival that were not seen under the treatment with
individual growth factors.
To our surprise, we found by morphometrical analysis
that OA chondrocytes deposited signiﬁcantly more ECM
than normal cells under the combined treatment with the
two growth factors. Previously25, no difference was de-
tected in PG production by normal and OA chondrocytes
under combined treatment when using the dimethylmethy-
lene blue assay. However, morphometrical analysis that
measures the net result of total matrix deposited by chon-
drocytes suggests that matrix proteins in addition to the
PGs are signiﬁcantly stimulated by IGF-1 plus OP-1 treat-
ment of OA cells. Among candidates responsible for such
difference could be perhaps type I collagen (in addition to
type II collagen and aggrecan)28, which was found in our
study mainly in OA chondrocytes treated with combined
OP-1 and IGF-1. We also detected more of collagen type
VI in OA chondrocytes under the combined treatment
than in any other group, which also could contribute to the
differences in the amount of deposited matrix by normal
and OA chondrocytes stimulated by the combination of
the two growth factors. Interestingly, only in the beads
with OA chondrocytes treated with OP-1þ IGF-1 most of
type VI collagen was detected in the interterritorial matrix
rather than being restricted to the pericellular matrix as
has been known for normal articular cartilage44e46. A similar
increase in type VI collagen in the ECM of OA cartilage has
been reported47,48. However, it is still unclear whether type
VI collagen is a native component of the OA ECM or repre-
sents remnants of the degradation products which diffuse inthis matrix. Apparently, type VI collagen was the only matrix
protein that was affected by the treatment with IGF-1 when
used alone in our study. This may provide additional sup-
portive evidence for an association between IGF-1 signaling
and type VI collagen in chondrocytes reported previously by
Loeser49. It has been shown that stimulation of chondro-
cytes with IGF-1 induces cell surface a1b1 integrin which
is a type VI collagen receptor50 and thus mediates chondro-
cyte adhesion to type VI collagen. Strong accumulation of
type VI collagen in the pericellular matrix of IGF-1 treated
cultures found in our study may be due to increased binding
of type VI collagen to the cell resulting from the concurrent
stimulation of a1b1 integrin levels.
We were not particularly surprised to ﬁnd minimal levels
of type X collagen under the combined treatment. Since
only combined treatment stimulated signiﬁcant cell prolif-
eration (unlike individual growth factors)25, it is possible
that proliferating chondrocytes may continue their pro-
grammed developmental pathway and undergo hypertro-
phy, where type X collagen expression is one of the
characteristic changes51. Low levels of type X suggest,
however, that only a small subpopulation of cells may
be hypertrophic.
Collectively, we found that combined treatment with IGF-1
and OP-1 induced more accumulation of matrix proteins in
the ECM than with each growth factor separately. The
larger matrix found in the combined group could be ex-
plained by a couple of reasons. First, the increased number
of metabolically active cells25 overall could produce more
matrix, although in this and previous studies25,51 all quanti-
tative data were normalized to the cell number. Secondly,
we think that the most real scenario is that each growth fac-
tor stimulates and promotes the signaling of a second factor
and together they may stimulate pathways that are not af-
fected by individual growth factors. Some evidence for
this hypothesis was provided in previous work24, where
OP-1 was shown to stimulate autocrine expression of
IGF-1 and its receptor. We also anticipate that OP-1 may
improve or restore the responsiveness of OA and old chon-
drocytes to the treatment with IGF-1. Studies have shown
that growth factors (EGF, FGF, TGF-b) may in fact modu-
late the response of chondrocytes to other growth
factors30e33,52. But the mechanism of this effect remains
to be veriﬁed. With regard to the role of OP-1 in IGF-1 sig-
naling, besides our work the combination of OP-1 and IGF-1
was extensively studied only in rat calvaria cells in the
laboratory of Dr. Lee 34e36, where a synergistic effect on
cell differentiation and proliferation was found for the two
growth factors.
In conclusion, the results obtained in the current study
suggest that combined therapy with IGF-1 and OP-1 may
be more effective in treating cartilage defects seen in OA.
The understanding of the mechanisms of the synergistic
response may provide important information needed to
design effective growth factor therapy for arthritis.
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